insitro Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
252
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$400M
- Investors
-
23
insitro General Information
Description
Operator of a data-driven drug discovery and development company intended to transform how drugs are discovered and delivered to patients. The company uses machine learning and high-throughput biology to create massive data sets to be brought to bear on key bottlenecks in pharmaceutical R&D, enabling drug development companies to have predictive models that are used to accelerate target selection, design, and develop effective therapeutics, and to inform clinical strategy.
Contact Information
Website
www.insitro.comCorporate Office
- 279 East Grand Avenue
- Suite 200
- South San Francisco, CA 94080
- United States
Corporate Office
- 279 East Grand Avenue
- Suite 200
- South San Francisco, CA 94080
- United States
insitro Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C) | 07-Apr-2021 | $400M | Completed | Pre-Clinical Trials | ||
| 2. Early Stage VC (Series B) | 26-May-2020 | Completed | Pre-Clinical Trials | |||
| 1. Early Stage VC (Series A) | 01-May-2018 | $100M | $100M | Completed | Pre-Clinical Trials |
insitro Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A2 | 18,359,806 | $0.000010 | 8% | $2.69 | $2.69 | 1x | $2.69 | 12.67% |
| Series A1 | 33,327,366 | $0.000010 | 8% | $0.9 | $0.9 | 1x | $0.9 | 23% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
insitro Comparisons
Industry
Financing
Details
insitro Competitors (4)
One of insitro’s 4 competitors is Exscientia, a Formerly VC-backed company based in Oxford, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Exscientia | Formerly VC-backed | Oxford, United Kingdom | ||||
| Numerion Labs | Venture Capital-Backed | San Francisco, CA | ||||
| Verge Labs | Venture Capital-Backed | San Francisco, CA | ||||
| Recursion Pharmaceuticals | Formerly VC-backed | Salt Lake City, UT |
insitro Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
insitro Patents
insitro Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4769296-A1 | Biological image transformation using machine-learning models | Pending | 31-Dec-2024 | ||
| US-20260055407-A1 | Compositions and methods for treating nonalcoholic fatty liver disease | Pending | 21-Aug-2024 | ||
| WO-2026044017-A2 | Compositions and methods for treating nonalcoholic fatty liver disease | Pending | 21-Aug-2024 | ||
| WO-2026044017-A3 | Compositions and methods for treating nonalcoholic fatty liver disease | Pending | 21-Aug-2024 | ||
| AU-2025263180-A1 | Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease | Pending | 25-Apr-2024 |
insitro Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
insitro Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ADS Ventures | Venture Capital | Minority | ||
| Globalive Capital | Family Office | Minority | ||
| HBM Genomics | Venture Capital | Minority | ||
| RONA Holdings | Venture Capital | Minority | ||
| SoftBank Investment Advisers | Growth/Expansion | Minority |
insitro Acquisitions (2)
insitro’s most recent deal was a Merger/Acquisition with CombinAble.AI. The deal was made on 29-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CombinAble.AI | 29-Jan-2026 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| Haystack Sciences | 22-Oct-2020 | Merger/Acquisition | Discovery Tools (Healthcare) |
insitro FAQs
-
When was insitro founded?
insitro was founded in 2018.
-
Where is insitro headquartered?
insitro is headquartered in South San Francisco, CA.
-
What is the size of insitro?
insitro has 252 total employees.
-
What industry is insitro in?
insitro’s primary industry is Drug Discovery.
-
Is insitro a private or public company?
insitro is a Private company.
-
What is the current valuation of insitro?
The current valuation of insitro is .
-
What is insitro’s current revenue?
The current revenue for insitro is .
-
How much funding has insitro raised over time?
insitro has raised $643M.
-
Who are insitro’s investors?
ADS Ventures, Globalive Capital, HBM Genomics, RONA Holdings, and SoftBank Investment Advisers are 5 of 23 investors who have invested in insitro.
-
Who are insitro’s competitors?
Exscientia, Numerion Labs, Verge Labs, and Recursion Pharmaceuticals are competitors of insitro.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
